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Malignancy Induced Hemophagocytic Lymphohistiocytosis
Shah, S MD, Patel, Jay MD, Osobamiro, O MD Department Of Internal
Medicine Henry Ford Macomb, Clinton Township

Introduction

Photos

Hemophagocytic Lymphohistiocytosis is a rare, aggressive and life threatening condition
characterized by excessive immune activation. In view of a variable clinical presentation,
lack of specificity of the clinical and laboratory findings and outcomes limited by delay in
identification warrants discussion to help in this challenging diagnosis.

Discussion
HLH is a life-threatening condition due to ineffective immunity and uncontrolled hyper-inflammatory
response. This is often a disease of the pediatric population, with the highest incidence in those <3
months. However more and more it is being found in adults even as old as 70 years of age. It can often
be triggered by infection, malignancy, and autoimmune disease. There are familial forms of this
disease as well which result from defects in NK cells and cytotoxic T-cells. Hemophagocytosis refers
to the literal phagocytotic engulfment of hematopoietic cells by macrophages activated in the bone
marrow. Macrophages in HLH also secrete excessive amounts of cytokines leading to tissue damage
and organ failure. Normally NK cells and cytotoxic T cells work to eliminate, damaged, stressed, or
unregulated cells. In HLH however these cells fail to do so and the normal feedback regulation is lost
resulting in continued macrophage activation and cytokine production. Triggers that have been
identified are often viral in nature, and often related to EBV.

HLH comes in two forms, primary and secondary HLH. Here we discuss secondary HLH
which by prevalence can be due to viral infections (29%), other infections (20%),
malignancies (27%), rheumatologic disorder (7%) and immune deficiency syndromes (6%).
Among the cases related to malignancy, most are due to hematologic malignancy. In children
hematologic malignancy related HLH is associated with B-lymphoblastic leukemia, and in
adults likely T cell lymphomas.

HLH normally presents as a febrile illness, with multiple organ systems involved. They can present
with a confounding picture as fever of unknown origin, hepatitis, or even encephalitis or meningitis.
Along with fever patients will often develop splenomegaly, bicytopenias, will have elevated LFTs and
triglycerides. One important marker is ferritin, which is often over 500 in 94% of patients. The main
cytopenia’s involved are anemia and thrombocytopenia with average hemoglobin around 7-8 and
platelet counts around 70,000. Ferritin levels can often be increased in iron overload
syndromes, sepsis, infections and liver failure, however at levels around 10,000 the specificity for
HLH is 96%. Neurologic abnormalities are common in HLH, and can be variable from seizures,
mental status changes, to ataxia. PRES syndrome can also be related to HLH. Pulmonary function and
respiratory distress often occur with HLH, in and ARDS like fashion, which often requires mechanical
ventilation.

Case Description
A 57-year-old female initially presented for a CT of the chest after failed
outpatient treatment for pneumonia; initial imaging denoted diffuse
lymphadenopathy, she followed up with Hematology/Oncology, having two fine
needle aspirations with inconclusive results.

The initial tests in HLH should be centered on that pathophysiology of the disease, including CBC w/
diff. coagulation studies, liver enzymes, Serum ferritin, LDH, and serum triglycerides. When clinical
judgment leads you to a cause of HLH, further testing such as blood cultures, bone marrow
evaluation, and imaging should be considered. Specialized testing can include Soluble IL-2 receptor,
NK cell function, and flow cytometry. Five of the eight criteria for HLH are required for a diagnosis.

Approximately 2 months later she presented to our ED with progressive
shortness of breath, hypoxia and chest pain associated with significant fatigue
and cough. Her initial physical examination was significant for only bilateral
crackles at the lung bases. CT PE was performed which showed significant
supraclavicular lymphadenopathy and subsegmental PE along with bibasilar
infiltrates. At this point lactic acid was performed which was elevated, and she
was diagnosed with PE, pneumonia and sepsis and admitted to the MICU and
started on broad-spectrum antibiotics and heparin drip.

Treatment for patients that are critically ill with HLH is centered on HLH specific chemotherapy,
which includes Etoposide and high dose steroids (dexamethasone), and intrathecal treatments if CNS
involvement is found. Supportive treatment with transfusions for anemia and thrombocytopenia
should be given as well to maintain platelet counts over 50,000. Long-term cure or the disease
requires hematopoietic cell transplant, and in the case of malignancy related HLH would require
allogenic transplant to stop recurrent HLH. The median survival of patient with HLH is 54% at 6
years. Higher ferritin levels at diagnosis, and slow decline in ferritin during treatment is also a poor
prognostic factor.

While in the ICU General surgery was consulted for excisional biopsy of any
reachable lymph node. Results from this biopsy showed Angioimmunoblastic T
cell lymphoma with EBV driven polymorphous B cell lymphoproliferation. In
post-op after the biopsy she became tachycardiac, tachypneiac and hypoxic. Over
the next 5 days, she became significantly anemic, thrombocytopenic, febrile,
hypercalcemic, hyperuricemic and hypofirbinogenemic, and developed
significant splenomegaly of 17 cm with worsening lactic acidosis.

Conclusion
HLH is a clinically rare condition that is increasing in prevalence and is still significantly
under recognized today. This case illustrates the necessity for early identification of HLH in
the setting of predisposing conditions such as malignancy and initiation of treatment,
especially in the setting of an unclear clinical picture delaying diagnosis. The high morbidity
and mortality associated with this condition can be attributed to under recognition and the
fulminant course of the disease, with the need for therapy to be initiated early for any
reasonable attempt to provide a favorable outcome. While strides have been made recently
in regards to treatment options increasing survival, this diagnosis remains devastating and
much work remains to raise awareness and improve effectiveness of treatments.

At this point HLH was considered and triglyceride levels along with ferritin and
IL-3 (CD25) receptor were ordered. She was found to have significantly elevated
ferritin and IL-2 along with high triglycerides and low fibrinogen. During this
time she was also exhibiting tumor lysis syndrome with elevated LDH and uric
acid, and became hemodynamically unstable; subsequently leading to the
patients’ death.
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